Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
characteristic reactions of these species and to examine the difference between these reactions and those of the corresponding conventional molecular ions. The term distonicion was coined by Radom and co-workersZ3 to describe radical cations arising (formally) by ionization of zwitterions or diradicals. The difference between the properties of stable distonicions and those of conventional molecular ions generated
一系列非张力自由基阳离子的特征反应表明,这些物种的气相化学与异构常规分子离子的气相化学有很大不同。通过在 C 或 N 处引入烷基取代基而衍生自 'CH2CHZNH3+ 的 15 种异张力自由基阳离子已被证明是稳定的物种,其反应是其结构的特征。主要的断裂和异构化过程如下:(i) CN 键的简单裂解,形成烯烃离子或烯烃分子,(ii) 质子化氨基的 1,2-迁移,以及 (iii) 形成铵离子烯基自由基的消除。在链长允许的情况下,这些反应可以先于或伴随着特定的分子内夺氢反应,这导致具有特征性不同反应的异构非张性离子。夺氢反应通常是可逆的;在长烷基存在下,可以发生异构化为胺分子离子(反之亦然)。相应地,许多低能胺分子离子的反应需要在碎裂之前异构化为非张力中间体。最近有相当多的论文证明了气相中存在稳定的非张力自由基阳离子,'-I4 和非张力离子越来越频繁地被认为是单分子裂解的关键中间体。这些物质的碰撞
VIRAL POLYMERASE INHIBITORS
申请人:STAMMERS Timothy
公开号:US20110230465A1
公开(公告)日:2011-09-22
Compounds of formula I:
wherein X, R
2
, R
3
, R
5
and R
6
are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.
HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
申请人:Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center
公开号:US20140066424A1
公开(公告)日:2014-03-06
The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
本发明涉及化合物和方法,可用作HIF通路活性的抑制剂,用于治疗或预防癌症和其他缺氧介导的疾病。
COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS
申请人:Alios Bio Pharma, Inc.
公开号:US20150238498A1
公开(公告)日:2015-08-27
Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).